PolyPid Ltd. (PYPD)
PYPDDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PYPD Earnings Report
EPS Est: $-0.34 | FQ end 2026-06 | Call: 2026-08-12 15:00:00
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
D-PLEX | Phase 3 | Abdominal Surgery | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PolyPid Ltd. (PYPD)'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PolyPid Ltd. (PYPD)'s (PYPD) pipeline across Phase 3. Its lead program is D-PLEX (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PolyPid Ltd. (PYPD)'s next FDA catalyst?→
PolyPid Ltd. (PYPD)'s (PYPD) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PYPD biotech catalysts?→
Add PYPD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PolyPid Ltd. (PYPD)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.